Satellos Bioscience Inc. Net Assets
Satellos Bioscience Inc. net assets. Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has net assets worth CA$59.81 Million CAD (≈ $43.27 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$65.66 Million ≈ $47.50 Million USD) and total liabilities (CA$5.85 Million ≈ $4.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Satellos Bioscience Inc. (MSCL) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$59.81 Million |
| % of Total Assets | 91.09% |
| Annual Growth Rate | 14.33% |
| 5-Year Change | 164.58% |
| 10-Year Change | 1099.43% |
| Growth Volatility | 298.48 |
Net Assets of Satellos Bioscience Inc. (2007–2025)
Net assets of Satellos Bioscience Inc. from 2007 to 2025. This chart illustrates how Satellos Bioscience Inc.'s net assets have evolved over time, based on quarterly financial data. See MSCL equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Satellos Bioscience Inc. (2007–2025)
The table below shows the annual net assets of Satellos Bioscience Inc. from 2007 to 2025. For live market cap and overall valuation, see Satellos Bioscience Inc. (MSCL) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$27.73 Million ≈ $20.06 Million |
-59.13% |
| 2024-12-31 | CA$67.86 Million ≈ $49.09 Million |
+66.84% |
| 2023-12-31 | CA$40.67 Million ≈ $29.42 Million |
+1107.30% |
| 2022-12-31 | CA$3.37 Million ≈ $2.44 Million |
-67.86% |
| 2021-12-31 | CA$10.48 Million ≈ $7.58 Million |
+5801.88% |
| 2020-12-31 | CA$-183.84K ≈ $-132.98K |
-144.99% |
| 2019-12-31 | CA$408.57K ≈ $295.56K |
+165.44% |
| 2018-12-31 | CA$-624.38K ≈ $-451.67K |
-157.46% |
| 2017-12-31 | CA$1.09 Million ≈ $786.11K |
-53.00% |
| 2016-12-31 | CA$2.31 Million ≈ $1.67 Million |
-38.84% |
| 2015-12-31 | CA$3.78 Million ≈ $2.74 Million |
-31.43% |
| 2014-12-31 | CA$5.51 Million ≈ $3.99 Million |
+324.25% |
| 2013-12-31 | CA$1.30 Million ≈ $940.12K |
-36.58% |
| 2012-12-31 | CA$2.05 Million ≈ $1.48 Million |
-23.80% |
| 2011-12-31 | CA$2.69 Million ≈ $1.95 Million |
+12.77% |
| 2010-12-31 | CA$2.38 Million ≈ $1.73 Million |
-44.47% |
| 2009-12-31 | CA$4.29 Million ≈ $3.11 Million |
+316.67% |
| 2008-12-31 | CA$1.03 Million ≈ $745.64K |
-58.62% |
| 2007-12-31 | CA$2.49 Million ≈ $1.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Satellos Bioscience Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7352286900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Satellos Bioscience Inc. Net Assets Breakdown (December 2025)
Satellos Bioscience Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$85.67 Million | 308.91% |
| Other Comprehensive Income | CA$13.73 Million | 49.52% |
| Other Components | CA$10.15 Million | 36.59% |
| Total Equity | CA$27.73 Million | 100.00% |
Satellos Bioscience Inc. Competitors by Market Cap
The table below lists competitors of Satellos Bioscience Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
King Polytechnic Engineering Co Ltd
TWO:6122
|
$138.16 Million |
|
Bitcoin Group SE
XETRA:ADE
|
$138.20 Million |
|
CYGNUS Metals Ltd
AU:CY5
|
$138.22 Million |
|
LG Household & Healthcare Ltd Pref
KO:051905
|
$138.22 Million |
|
Capacit'e Infraprojects Limited
NSE:CAPACITE
|
$138.12 Million |
|
Land General Bhd
KLSE:3174
|
$138.09 Million |
|
Baozun Inc
NASDAQ:BZUN
|
$138.03 Million |
|
Tucows Inc.
TO:TC
|
$137.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Satellos Bioscience Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 67,862,000 to 27,733,437, a change of -40,128,563 (-59.1%).
- Net loss of 25,308,414 reduced equity.
- Share repurchases of 2,241,000 reduced equity.
- Other comprehensive income increased equity by 13,951,958.
- Other factors decreased equity by 26,531,107.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-25.31 Million | -91.26% |
| Share Repurchases | CA$2.24 Million | -8.08% |
| Other Comprehensive Income | CA$13.95 Million | +50.31% |
| Other Changes | CA$-26.53 Million | -95.66% |
| Total Change | CA$- | -59.13% |
Book Value vs Market Value Analysis
This analysis compares Satellos Bioscience Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.07x to 4.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CA$131.65 | CA$9.00 | x |
| 2008-12-31 | CA$12.32 | CA$9.00 | x |
| 2009-12-31 | CA$34.89 | CA$9.00 | x |
| 2010-12-31 | CA$14.01 | CA$9.00 | x |
| 2011-12-31 | CA$15.38 | CA$9.00 | x |
| 2012-12-31 | CA$9.94 | CA$9.00 | x |
| 2013-12-31 | CA$5.07 | CA$9.00 | x |
| 2014-12-31 | CA$15.67 | CA$9.00 | x |
| 2015-12-31 | CA$10.74 | CA$9.00 | x |
| 2016-12-31 | CA$6.57 | CA$9.00 | x |
| 2017-12-31 | CA$3.09 | CA$9.00 | x |
| 2018-12-31 | CA$-1.77 | CA$9.00 | x |
| 2019-12-31 | CA$0.15 | CA$9.00 | x |
| 2020-12-31 | CA$-0.07 | CA$9.00 | x |
| 2021-12-31 | CA$5.22 | CA$9.00 | x |
| 2022-12-31 | CA$1.13 | CA$9.00 | x |
| 2023-12-31 | CA$5.65 | CA$9.00 | x |
| 2024-12-31 | CA$7.09 | CA$9.00 | x |
| 2025-12-31 | CA$1.90 | CA$9.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Satellos Bioscience Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-91.26%) is above the historical average (-142.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -207.90% | 0.00% | 0.00x | 1.31x | CA$-5.43 Million |
| 2008 | -268.06% | 0.00% | 0.00x | 1.43x | CA$-2.87 Million |
| 2009 | -53.61% | 0.00% | 0.00x | 1.07x | CA$-2.73 Million |
| 2010 | -130.03% | -3104.65% | 0.04x | 1.12x | CA$-3.34 Million |
| 2011 | -38.35% | 0.00% | 0.00x | 1.09x | CA$-1.30 Million |
| 2012 | -177.72% | 0.00% | 0.00x | 1.47x | CA$-3.85 Million |
| 2013 | -436.49% | 0.00% | 0.00x | 3.03x | CA$-5.80 Million |
| 2014 | -36.50% | 0.00% | 0.00x | 1.29x | CA$-2.56 Million |
| 2015 | -47.48% | 0.00% | 0.00x | 1.03x | CA$-2.17 Million |
| 2016 | -64.39% | 0.00% | 0.00x | 1.06x | CA$-1.72 Million |
| 2017 | -113.80% | 0.00% | 0.00x | 1.27x | CA$-1.35 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.64 Million |
| 2019 | -474.39% | -7752.94% | 0.02x | 2.63x | CA$-1.98 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-1.56 Million |
| 2021 | -147.92% | 0.00% | 0.00x | 1.20x | CA$-16.55 Million |
| 2022 | -336.06% | 0.00% | 0.00x | 1.84x | CA$-11.66 Million |
| 2023 | -39.06% | 0.00% | 0.00x | 1.09x | CA$-19.96 Million |
| 2024 | -41.41% | 0.00% | 0.00x | 1.08x | CA$-34.89 Million |
| 2025 | -91.26% | 0.00% | 0.00x | 1.15x | CA$-28.08 Million |
Industry Comparison
This section compares Satellos Bioscience Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,150,773
- Average return on equity (ROE) among peers: -5.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Satellos Bioscience Inc. (MSCL) | CA$59.81 Million | -207.90% | 0.10x | $138.13 Million |
| Appili Therapeutics Inc (APLI) | $-10.92 Million | 0.00% | 0.00x | $464.29K |
| Aptose Biosciences Inc (APS) | $118.92 Million | -46.45% | 0.06x | $4.43 Million |
| Arch Biopartners Inc (ARCH) | $-3.88 Million | 0.00% | 0.00x | $43.24 Million |
| Biomind Labs Inc (BMND) | $-1.43 Million | 0.00% | 0.00x | $19.92 Million |
| Cybin Inc (CYBN) | $1.45 Million | 0.00% | 0.18x | $301.37 Million |
| Eastwood Bio-Medical Canada Inc (EBM) | $1.31 Million | -44.19% | 0.26x | $89.55 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $45.77 Million | -76.33% | 0.10x | $353.56 Million |
| Devonian Health Group Inc (GSD) | $5.19 Million | 111.16% | 1.26x | $12.57 Million |
| Helix BioPharma Corp. (HBP) | $-844.00K | 0.00% | 0.00x | $50.83 Million |
| Hemostemix Inc (HEM) | $-4.05 Million | 0.00% | 0.00x | $6.82 Million |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more